Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.78 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.75 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.75 |
| ▸ | KDR | P35968 | 5/20 | 0.73 |
| ▸ | RET | P07949 | 2/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.72 |
| ▸ | LCK | P06239 | 4/20 | 0.72 |
| ▸ | FLT3 | P36888 | 2/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
| ▸ | ROS1 | P08922 | 1/20 | 0.69 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.69 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.69 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.67 |
| ▸ | STK10 | O94804 | 1/20 | 0.67 |
| ▸ | JAK3 | P52333 | 1/20 | 0.67 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.67 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.67 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30141491 | 1.00 | EGFR (0.78) | EGFRERBB2RIPK2EPHB2KDR | |
| Hydrochloric Acid SCHEMBL8809813 | 0.99 | EGFR (0.76) | EGFRERBB2RIPK2EPHB2KDR | |
| SCHEMBL8808387 | 0.95 | EGFR (0.75) | EGFRERBB2RIPK2EPHB2KDR | |
| SCHEMBL30891782 | 0.92 | EGFR (0.83) | EGFRERBB2RIPK2EPHB2KDR | |
| Trifluoroacetic Acid SCHEMBL20494312 | 0.91 | EGFR (0.72) | EGFRERBB2RIPK2EPHB2KDR | |
| SCHEMBL15607659 | 0.91 | EGFR (0.78) | EGFRERBB2RIPK2EPHB2KDR | |
| Hydrochloric Acid SCHEMBL8364042 | 0.91 | EGFR (0.70) | EGFRERBB2RIPK2EPHB2KDR | |
| SCHEMBL1387156 | 0.90 | EGFR (0.75) | EGFRERBB2RIPK2EPHB2KDR | |
| Hydrochloric Acid SCHEMBL8810888 | 0.89 | EGFR (0.68) | EGFRERBB2RIPK2EPHB2ERBB4 | |
| Hydrochloric Acid SCHEMBL8811182 | 0.89 | EGFR (0.76) | EGFRERBB2RIPK2EPHB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400033-B1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORP (JP) | 2013-02-20 | — | — | EP | claimed |
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | SANTARIS PHARMA A/S (DK) | 2012-03-29 | — | — | US | claimed |
| CN-102395374-A | Methods of treating cancers with her3 antisense oligonucleotides | ENZON PHARMACEUTICALS INC | 2012-03-28 | — | — | CN | claimed |
| EP-2419110-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | Enzon Pharmaceuticals, Inc. (US) | 2012-02-22 | — | — | EP | claimed |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ENZON PHARMACEUTICALS, INC. (US) | 2012-01-05 | — | — | US | claimed |
| US-20110318768-A1 | METHOD FOR DETERMINING SENSITIVITY OF TUMOR CELLS TO TYROSINE KINASE INHIBITOR AND COMPUTER PROGRAM PRODUCT | SYSMEX CORPORATION (JP) | 2011-12-29 | — | — | US | claimed |
| EP-2400033-A1 | Method for determining sensitivity of tumor cells to tyrosine kinase inhibitor and computer program product | SYSMEX CORPORATION (JP) | 2011-12-28 | — | — | EP | claimed |
| EP-2376087-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | Santaris Pharma A/S (DK) | 2011-10-19 | — | — | EP | claimed |
| WO-2010120861-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ENZON PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | WO | claimed |
| WO-2010054051-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | SANTARIS PHARMA A/S (DK) | 2010-05-14 | — | — | WO | claimed |
| WO-2007047489-A2 | COMPOSITIONS AND METHODS FOR USE IN CANCER THERAPY | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | claimed |
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | claimed |
| JP-H10505600-A | — | — | 1998-06-02 | — | — | JP | claimed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | claimed |
| US-20240309327-A1 | CARDIOMYOCYTE PRODUCTION METHOD | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-09-19 | — | — | US | disclosed |
| EP-4424819-A1 | METHOD FOR PRODUCING MYOCARDIAL CELL LAYER, MYOCARDIAL CELL LAYER, AND USE THEREOF | FUJIFILM Corporation (JP) | 2024-09-04 | — | — | EP | disclosed |
| WO-2004013091-A2 | 4-ANILIDO SUBSTITUTED QUINAZOLINES AND USE THEREOF AS INHIBITORS OF EPIDERMAL GROWTH FACTOR RECEPTOR KINASES | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-02-12 | — | — | WO | disclosed |
| EP-0782570-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1997-07-09 | — | — | EP | disclosed |
| WO-1996009294-A1 | SUBSTITUTED HETEROAROMATIC COMPOUNDS AND THEIR USE IN MEDICINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076781-A1 | METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885RIPK2 2387/4885 |
| US-20120004285-A1 | ERBB-3 (HER3)-SELECTIVE COMBINATION THERAPY | ERBB3, ERBB2, EGFR | EGFR 3/4885ERBB2 2/4885RIPK2 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.